Amgen Inc (BUE:AMGN)
ARS 10425 -25 (-0.24%) Market Cap: 153.50 Til Enterprise Value: 205.37 Til PE Ratio: 36.22 PB Ratio: 20.20 GF Score: 57/100

Q4 2023 Amgen Inc Earnings Call Transcript

Feb 06, 2024 / 09:30PM GMT
Release Date Price: ARS13193.5 (-5.00%)
Operator

My name is Julianne, and I will be your conference facilitator today for Amgen's Fourth Quarter 2023 Financial Results Conference Call. (Operator Instructions) I would now like to introduce Justin Claeys, Vice President of Investor Relations. Mr. Claeys, you may now begin.

Justin Claeys

Thank you, Julianne. Good afternoon, and welcome to our fourth quarter 2023 earnings call. Bob Bradway will lead the call and be followed by a broader review of our performance by Murdo Gordon; Vikram Karnani; Jay Bradner, who I'm pleased to welcome and is joining us for the first time on our quarterly earnings call; and Peter Griffith. Dave Reese will also be available during the Q&A session.

Given the timing of the Horizon Therapeutics acquisition close, the results as shown in our press release and slides include contribution from the Horizon business from October 6 onwards. For the avoidance of doubt, this will also be the basis for our filed financial results. To supplement this information, Vikram will also provide sales information for these products for the full

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot